🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
2026-525324-26-00Schizophrenia spectrum disorder (SSD)
Region Oerebro Laen
Mental Disorders
Sweden
05/06/2026
Phase II
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
2026-526494-42-00Gastric cancer
Varsinais-Suomen hyvinvointialue
Neoplasms
Finland
05/06/2026
Phase II
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
2026-525817-29-00Multiple Sclerosis; Primary Progressive Multiple Sclerosis;…
Sundance Biosciences Inc.
Nervous System Diseases
Finland
05/06/2026
Phase II
Cosmos Trial: Cerebroprotection Of AST-004 in Mild Complicated Traumatic Brain Injuries
2026-525554-11-00Traumatic brain injury
Astrocyte Pharmaceuticals Inc.
Nervous System Diseases
Netherlands
04/06/2026
Phase II
Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
2025-524720-22-00patients with head and neck squamous cell carcinoma (HNSCC)
Fakultni Nemocnice Kralovske Vinohrady
Otorhinolaryngologic Diseases
Czechia
02/06/2026
Phase II
A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial
2025-523570-17-00Parkinson's Disease
Helse Bergen HF
Nervous System Diseases
Norway
02/06/2026
Phase II
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
2025-521126-15-00Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
Neoplasms
Spain
01/06/2026
Phase II
Sublingual Birch Immunotherapy for Pollen-associated Food Allergy
2025-523653-34-00Birch pollen Allergy, Pollen-associated Food Allergy
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
Immune System Diseases
Germany
29/05/2026
Phase II
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles
Hemic and Lymphatic Diseases
Germany, France, Czechia, Netherlands, Spain
29/05/2026
Phase II
Leveraging the neural mechanisms of social reward for drug relapse prevention
2023-504518-31-01substance use disorder
Fondazione Santa Lucia IRCCS
Mental Disorders
Italy
29/05/2026
Phase II
Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS
2026-525613-31-00Restless legs syndrome
Centre Hospitalier Universitaire De Montpellier
Nervous System Diseases
France
29/05/2026
Phase II
J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo
2025-524726-18-00Non-Segmental Vitiligo (NSV), Vitiligo
Eli Lilly & Co.
Immune System Diseases
Poland, Belgium
29/05/2026
Phase II
Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.
2026-525317-31-00Retractile Capsulitis
Centre Hospitalier Universitaire De Nantes
Musculoskeletal Diseases
France
29/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
2025-523400-72-00Cystic fibrosis
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults with Generalized Myasthenia Gravis
2025-523950-15-01Generalized Myasthenia Gravis
Vertex Pharmaceuticals Inc.
Nervous System Diseases
Poland
29/05/2026
Phase II
Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)
2025-524378-40-00Locally advanced high‑risk stage III rectal adenocarcinoma …
Institut Gustave Roussy
Neoplasms
France
28/05/2026
Phase II
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc.
Neoplasms
Bulgaria, France, Spain
28/05/2026
Phase II
Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)
2025-522781-77-01Epstein-Barr virus infection
Helse Bergen HF
Virus Diseases
Norway
28/05/2026
Phase II
Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.
2024-516796-33-00The medical condition studied in IMMUNO-BOS is Bronchioliti…
Hospital Foch
Respiratory Tract Diseases
France
27/05/2026
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
2025-523579-47-00moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG
Immune System Diseases
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase II
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…
Maplight Therapeutics Inc.
Mental Disorders
Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary
27/05/2026
Phase II
POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug
2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris
Musculoskeletal Diseases
France
26/05/2026
Phase II
Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis
2025-524885-12-00Osteoarthritis
Radboud universitair medisch centrum Stichting
Musculoskeletal Diseases
Netherlands
26/05/2026
Phase II
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
2025-524181-26-00relapsed/refractory multiple myeloma
C4 Therapeutics Inc.
Hemic and Lymphatic Diseases
Italy, France, Spain, Poland
25/05/2026
Phase II
UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis
2025-521982-29-00Adult patients with advanced hormone receptor positive (HR+…
Unicancer
Neoplasms
France
22/05/2026
Rows per page Showing 201–225 of 726
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.